explore -WSS

explore

author：knowledge 2025-09-27 13:04:47 - browse：6

In a surprise move, the Food and Drug Administration has called for a meeting of outside advisers to discuss whether an Alzheimer’s drug from Eli Lilly should be approved, even as many outsiders expected the medicine to receive regulatory clearance this month.

The drug, donanemab, succeeded in its Phase 3 trial, resulting in a 35% slowing of Alzheimer’s disease progression versus placebo. But Lilly on Friday said that the FDA expects to call a meeting of an advisory committee to review the trial, saying that the agency had told the company “it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design” of the study.

A date for the meeting has not been set yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Eyeing GLP

entertainment

WSS

Reports of telehealth's death have been greatly exaggerated

At ASCO, AstraZeneca reports strong data for breast cancer drug

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Liver decline slowed by off

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

See how much Covid

focus

explore

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

NIH documents show early flaws of $1.6 billion long Covid program

Medicare proposal to cover medical devices draws a mixed reaction

Investigation reveals sickle cell patients pressured into sterilizations

23andMe had bad news about my health. I wish a person had delivered it

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Heart attack and stroke risk calculators need revising

For longer

At least 13 dead in Texas as scorching temps continue

At ASCO, AstraZeneca reports strong data for breast cancer drug

Wikipedia

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Innovation in antibiotics is ailing. 'Brain drain' may kill it

For longer

Let's speed up science by embracing open access publishing

H5N1 bird flu outbreak: Second human case reported, in Michigan

Wikipedia

knowledge

entertainment

hotspot